Drug Landscape ›
Belladonna and Opium ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 24
Most-reported reactions
Urticaria — 4 reports (16.67%) Drug Hypersensitivity — 3 reports (12.5%) Pruritus — 3 reports (12.5%) Abdominal Pain Lower — 2 reports (8.33%) Anaemia — 2 reports (8.33%) Anosmia — 2 reports (8.33%) Asthenia — 2 reports (8.33%) Blood Pressure Decreased — 2 reports (8.33%) Chest Pain — 2 reports (8.33%) Chronic Spontaneous Urticaria — 2 reports (8.33%)
Source database →
Belladonna and Opium in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Belladonna and Opium approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Belladonna and Opium in United States?
University of Washington is the originator. The local marketing authorisation holder may differ — check the official source linked above.